Fig. 1From: Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studiesChange in monthly migraine days during 12 weeks A) overall and B) by migraine classification. Data shown are the LSM changes from baseline in the monthly average number of migraine days during 12 weeks of double-blind treatment. Part A includes data for participants ≥60 years and the overall pooled population; part B includes data for participants ≥60 years by migraine diagnosis (chronic or episodic migraine). LSM, least-squares mean; LSMD, least-squares mean difference; SE, standard error. aP < 0.01 vs placebo. bP < 0.005 vs placebo. cP < 0.0001 vs placebo. dP < 0.05 vs placeboBack to article page